The non-essential amino acids serine and glycine are used in multiple anabolic processes that support cancer cell growth and proliferation (reviewed in ref. 1). While some cancer cells upregulate de novo serine synthesis [2] [3] [4] , many others rely on exogenous serine for optimal growth [5] [6] [7] . Restriction of dietary serine and glycine can reduce tumour growth in xenograft and allograft models 7, 8 . Here we show that this observation translates into more clinically relevant autochthonous tumours in genetically engineered mouse models of intestinal cancer (driven by Apc inactivation) or lymphoma (driven by Myc activation). The increased survival following dietary restriction of serine and glycine in these models was further improved by antagonizing the anti-oxidant response. Disruption of mitochondrial oxidative phosphorylation (using biguanides) led to a complex response that could improve or impede the anti-tumour effect of serine and glycine starvation. Notably, Kras-driven mouse models of pancreatic and intestinal cancers were less responsive to depletion of serine and glycine, reflecting an ability of activated Kras to increase the expression of enzymes that are part of the serine synthesis pathway and thus promote de novo serine synthesis.
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To assess the effect of dietary serine and glycine (SG) restriction in autochthonous tumour models, we used genetically engineered mouse models (GEMMs) of lymphoma (Eμ-Myc) and intestinal tumours (defective Apc). Eμ-Myc mice develop pre-neoplastic lesions within 28-42 days after birth 9 , and adenoma initiation is evident days after birth in Apc Min/+ mice 10 . Accordingly, Apc Min/+ mice carried high tumour numbers at 80 days, which subsequently increased in size but not number (Extended Data Fig. 1a ). Transferring mice from normal chow diet to experimental diets 60-80 days after birth showed that an SG-free diet significantly extended survival in these models carrying pre-malignant lesions (Fig. 1a, b) , with a slightly lower tumour burden in Apc Min/+ mice on the SG-free diet at clinical end point (Extended Data  Fig. 1a ). The diet reproducibly decreased serum SG from around 150 μ M to 65 μ M (Fig. 1c-e ); transferring mice to the SG-free diet a week after induction. Again, the experimental diet caused a significant increase in survival compared to control diet (containing purified amino acids) or normal chow (containing whole protein as a source of amino acids) (Fig. 1f) .
To test the effect of SG starvation on larger, established tumours (to mimic a therapeutic intervention), we transferred mice carrying measurable HCT116 (an invasive human colorectal cancer cell line) tumours onto the SG-free diet, which significantly retarded tumour growth (Extended Data Fig. 3a) . The in vitro growth of HCT116 cells was similarly diminished (in a cell-autonomous context) under SG concentrations detected in tumours (Extended Data Fig. 3b-d) . Using subcutaneous allografts of Eμ-Myc tumour cells, we transferred mice to SG-free diet after tumour formation and collected the tumours at a single temporal end point (6 days post diet change). Even with this relatively short period of SG restriction, a trend towards decreased tumour volume and cell number was seen, although no differences in cleaved caspase-3 (a marker of apoptosis) or BrdU incorporation (a marker of proliferation) were detected (Extended Data Fig. 4a-c) . However, haematoxylin and eosin staining showed a clear increase in necrosis in cross-sections of tumours from mice on the SG-free diet (Extended Data Fig. 4d , e). Apc Min/+ mice analysed at temporal end point (14 days post diet change) showed a trend for decreased cell number and increased apoptosis (Extended Data Fig. 4f ) but no evidence of necrosis, suggesting that tumour-specific factors, such as tissue of origin, tumour size and proliferation rate, influence tumour response.
Serine starvation activates de novo serine synthesis, diverting glycolytic intermediates away from energy production 11, 12 . Cells respond by increasing oxidative phosphorylation to maintain ATP turnover, and inhibiting oxidative phosphorylation (for example, by using biguanides to inhibit mitochondrial complex I) can enhance the anti-proliferative effect of serine starvation 7, 8 . A maximal dose (100 mg kg −1 per day) 13 of the biguanide phenformin was tolerated by Eμ-Myc mice on the control diet, but elicited marked toxicity (symptoms resembling dyschezia) in Eμ-Myc mice on the SG-free diet. While this prevented further recruitment, mice that survived on the SG-free diet with phenformin (7/14) did not suffer further adverse effects, and showed a trend for improved survival compared to animals on the SG-free diet alone (Fig. 2a) , consistent with a previous study in a tumour allograft system 8 
.
Metformin is a biguanide with lower toxicity than phenformin that is widely used in the clinic as an anti-diabetic agent and is being trialled as an anti-cancer agent 14 . While systemic availability of oral metformin is generally poor, some tissues (including the intestine) express OCT1 transporters that facilitate metformin uptake 15 . In humans, metformin doses of 0.5-1 g per day have been used in multiple clinical trials in colorectal cancer 14 . Using a dose of metformin (200 mg kg −1 per day) in mice equivalent (by body surface area calculation 16 ) to a daily human dose of 1 g per day, we failed to detect a significant impact of metformin on the survival of Apc Min/+ mice, although the beneficial effect of SG-starvation persisted ( Fig. 2b and Extended Data Fig. 5a ). Intriguingly, metformin increased the number of tumours in the SG-free diet group (Fig. 2c) , without impacting average tumour area (Extended Data Fig. 5b ).
Serum metformin ranged from 2 to 22 μ M in Apc Min/+ mice, with tissue metformin concentration ranging from 0.1 to 11 μ M (Extended Data Fig. 6a-c) , consistent with metformin pharmacokinetics in other tumour-bearing mice given metformin in drinking water 17, 18 . No difference in serum glucose and lactate levels were seen (Extended Data Fig. 6d ), indicating that this dose had minimal impact on systemic metabolism. Using Vil1-creER;Apc fl/fl mouse-derived organoids to assess the cell-autonomous effects of metformin showed that high letter reSeArCH metformin doses inhibited organoid growth as expected. Notably, a lower metformin dose (20 μ M) tended to increase organoid size (Fig. 2d) , although this did not reach statistical significance. While complex I inhibition by biguanides can increase the levels of reactive oxygen species (ROS), metformin also has anti-oxidant properties [19] [20] [21] [22] and we have shown that limiting ROS improves cell survival during SG Min/+ (c, control, n = 14; − SG, n = 13) and Eμ-Myc (d, control, n = 24; − SG, n = 24) cohorts were analysed by liquid chromatography-mass spectrometry (LC-MS), relative abundance (by metabolite peak area) is shown. Ctrl, control. Error bars are s.d., P values were calculated by t-test (unpaired, two-tailed). See Extended Data Fig. 2 for relative quantification of all amino acids. e, Serum concentration for serine and glycine in the Apc Min/+ cohort (control, n = 14; − SG, n = 13) was determined using six-point calibration curves with 13 C-15 N-labelled serine and glycine diluted in serum. Error bars are s.d., P values were calculated by t-test (unpaired, two-tailed). f, Lgr5-creER;Apc fl/fl mice were induced at 7-10 weeks of age, diet was changed seven days after first tamoxifen treatment and maintained until clinical end point (intestinal-tumour-related survival). Survival is calculated from first tamoxifen treatment. For all survival plots, P values calculated by Mantel-Cox test; NS, not significant. n, number of mice; MS, median survival in days. See Source Data. (Fig. 1a) . Consistently, under SG starvation, low-dose metformin decreased ROS levels, while higher doses increased ROS (Fig. 2e) . Treatment of SG-starved organoids with another ROS inducer (daunorubicin) decreased growth and increased ROS at low and high doses (Extended Data Fig. 6e, f) . The differential effect of metformin on the response to SG starvation therefore correlates with its potential antiand pro-oxidant effects, although further studies will be necessary to fully explore the role of biguanides and ROS in this context.
Our study suggests that the metformin levels achieved in our GEMMs were too low to inhibit tumour growth. Although the metformin doses used here were comparable with clinically effective doses for diabetes treatment in humans, species differences in the pharmacodynamics and/or pharmacokinetics of metformin could make it difficult to translate these responses from mouse to humans 17, 18 . While the response to metformin is dose-dependent, our data support the results of in vitro studies that show that manipulating ROS can modulate the response of tumours to SG starvation 7 . To test directly whether increasing ROS in vivo could enhance the anti-tumour effect of the SG-free diet, we used Tigar −/− mice that do not express Tigar, a protein that can support tumour development by limiting ROS [23] [24] [25] [26] . While Eμ-Myc expression on this mixed strain background caused mice to die of lymphoma more rapidly than pure BL6 Eμ-Myc mice (shown in Fig. 2a ), a combination of Tigar deletion with SG-free diet produced a significantly additive overall increase in survival (Fig. 2f) . Many chemotherapeutics and radiotherapy induce ROS, suggesting that there may be a benefit to combining this diet with standard anti-cancer treatments.
Previous studies have shown that the response to SG starvation can be modulated by other genetic alterations in the tumour, including amplification of the serine synthesis pathway (SSP) enzymes (making cells less reliant on extracellular serine) or loss of the tumour suppressor p53 (increasing vulnerability to serine starvation) 3, 7 . Surprisingly, two mouse models of pancreatic cancer (PDAC) driven by activation of Kras with either loss (Pdx1-cre;Kras G12D/+ ;Trp53 fl/+ ) or mutation (Pdx1-cre;Kras
27,28 showed no significant change in survival in response to SG-free diet, despite a clear decrease in serum SG levels ( , potentially negating dependence on extracellular serine. Using the Kras G12D -inducible cells, we found a consistent decrease in SSP enzyme expression at both the RNA and protein level following downregulation of Kras expression (Fig. 3c, d and Extended Data Fig. 9c ). Cells induced to express activated Kras were resistant to SG starvation, whereas non-induced cells were sensitive to SG starvation (Fig. 3e) . PDAC tumours of both genotypes responded to dietary SG restriction by upregulating SSP enzyme expression, a response that was not seen in the starvation-sensitive Eμ-Myc tumours (which do not have activated Kras) (Extended Data Fig. 9d ). Glycine levels and the GSH/GSSG ratio were maintained in PDAC but not Eμ-Myc tumours on SG-free diet (Extended Data Fig. 10a ). Unbiased metabolomics confirmed that serine and glycine were the major metabolites depleted by the diet in tumours from Eμ-Myc mice (Extended Data Fig. 10b ).
Vil1-creER;Apc fl/fl intestinal tumour organoids grow rapidly in vitro, but after five days in SG-free medium their ability to recover and grow was severely impaired. Addition of activated Kras allowed recovery from starvation and continued growth (Fig. 4a, b ). These differences were reflected in higher basal expression of the genes encoding SSP enzymes in the activated Kras-expressing cells (Fig. 4c) . Growth of organoids in labelled glucose showed that labelled serine levels (derived from glucose through the SSP) were higher in the Kras G12D cells, indicating increased rates of serine synthesis ( letter reSeArCH intestinal tissue showed that while Apc deregulation alone increased Psat1 and Psph expression-probably reflecting the ability of β-catenindriven Myc to support SSP expression 34 -the addition of activated Kras further enhanced SSP enzyme expression (Fig. 4e) mice, which have survival times comparable to our Apc-only models, and transferred mice to diet before Cre induction. In line with the ability of activated Kras to upregulate SSP enzyme expression, Kras G12D expression abrogated the pro-survival effect of the SG-free diet (Fig. 4f ) , although a trend for decreased tumour area was retained (Extended Data Fig. 10c ). We show that dietary limitation of SG can be effective in the treatment of some cancers, although whether dietary SG restriction would change serum or tumour amino acid levels in humans remains unknown. Combination of diet with agents that increase ROS is predicted to increase the therapeutic response. While elevation of SSP enzyme expression following Kras activation will make tumours less responsive to serine starvation treatment, the overall sensitivity of tumour cells to serine depletion will depend on the combinatorial effect of multiple genetic alterations. So although activation of Myc (directly or following Apc loss) can enhance SSP enzyme expression, the Eμ-Myc lymphoma model remained sensitive to SG starvation. In this context, mutation of Kras further enhanced SSP expression and increased resistance to the SG-free diet. By contrast, despite carrying activated Kras, HCT116 cells remain partially sensitive to SG depletion-a dependency that is further exacerbated by loss of p53 (ref. 7) . A role for other tumour associated changes has recently been demonstrated in a study showing LKB1 deletion enhances activation of the SSP 35 . We therefore anticipate that while individual genetic alterations can give an indication of the sensitivity of cancers to SG limitation, the final response will be influenced by both tissue of origin 36 and its wider genetic landscape.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. . Cell culture media were purchased from Gibco (Thermo Fisher Scientific), product numbers are shown in parentheses. iKras (DMEM -21969) and HCT116 cells (RPMI-1640 -31870) were maintained in the stated media supplemented with 10% FBS (10270), penicillin-streptomycin and amphotericin with l-glutamine at final concentration of 2 mM. Stock iKras cells were grown in the presence of doxycycline 2 μ g ml −1 (Kras-ON) and in medium with/without doxycycline (Kras-ON/OFF) for experiments. Cells were maintained in 37 °C, 5% CO 2 humidified incubators. Cultured cells were routinely tested for mycoplasma using Mycoalert detection kit (Lonza). Proliferation assays. iKras cells were seeded in complete DMEM medium plus doxycycline 2 μ g ml −1 in 24-well plates and allowed to adhere overnight. Cells were then washed with PBS and received either assay medium with or without SG, with or without doxycycline 2 μ g ml −1 . HCT116 cells (2.5 × 10 4 per well) were seeded in complete RPMI medium in 24-well plates and allowed to adhere overnight. Cells were then washed with PBS and received modified MEM medium supplemented with various concentrations of SG 7 . Medium was replaced with fresh medium every 24 h. Wells were counted (using Casy TT cell counter, Innovatis, Roche Applied Science) at the stated time points, using a 'time = 0' plate to calculate relative cell number from time of medium change. mice were induced with 80 mg kg −1 tamoxifen at 8-10 weeks, and crypts were isolated from intestinal tissue 3-4 days after induction (1 day before humane clinical end point in this model). Organoids were grown in Advanced DMEM/F-12 (ADF), supplemented with 2 mM glutamine, 1% penicillin-streptomycin solution, 0.1% AlbuMAX I BSA, 10 mM HEPES (all Gibco, Thermo Fisher Scientific). Adenomatous small intestine tissue was excised and cut into smaller pieces and washed five times with ice-cold PBS. Pieces were incubated in 5 mM EDTA for 10 min at 4 °C on a roller. Crypts were washed two times with ice-cold PBS to remove EDTA and incubated in 10× trypsin for 30 min at 37 °C. The cryptenriched supernatant was collected and washed approximately five times with 5 ml ADF through mechanical pipetting. Crypts were pelleted via centrifugation at 1,200 r.p.m. for 5 min. Crypts were re-suspended in growth-factor-reduced Matrigel (BD Biosciences) and 20 μ l was plated per well in a 12-well plate. Matrigel was allowed to solidify for 30 min in a 37 °C incubator before appropriate ADF was added supplemented with 0.05 μ g ml −1 EGF and 0.1 μ g ml −1 noggin (Total volume per well 1 ml). Crypts were split by harvesting in ice-cold PBS and spun down at 600 r.p.m. for 3 min. Supernatant was aspirated and the pellet dissociated with 100 μ l ice-cold PBS using mechanical pipetting. Five millilitres of PBS was added to tube and spun down at 600 r.p.m. for 3 min, repeated until supernatant was clear of debris. The final crypt pellet was re-suspended with growthfactor-reduced Matrigel and plated as before. For SG starvation, amino-acid-free Advanced DMEM/F-12 (Gibco, Thermo Fisher Scientific) was used to construct assay medium for organoids with or without SG (0.2 mM), containing all other amino acids. For LCMS analysis organoids were grown in 12-well plates in complete medium for three days. Medium was aspirated and organoids were washed with PBS. The medium was replaced with glucose-free Advanced DMEM/F-12 (Gibco, Thermo Fisher Scientific) supplemented with 15 mM 13 C 6 -glucose (CK-Gas/Cambridge Isotopes). After five hours media was aspirated, organoids were briefly washed in PBS and metabolites were extracted as described below. Organoid imaging. Organoids were seeded in the stated media with or without metformin/daunorubicin (both from Sigma-Aldrich) and allowed to grow for two days. Images for size quantification (performed using ImageJ software) were taken using a light microscope then organoids were fixed in 4% paraformaldehyde. ROS damage was assessed by immunostaining organoids with anti-malondialdehyde (MDA) (Abcam, ab6463), with Alexa Fluor 594 secondary antibody (Thermo Fisher Scientific). Images were captured on an Olympus FV1000 inverted laser scanning confocal microscope and MDA staining was quantified using ImageJ software. Liquid chromatography-mass spectrometry (LC-MS). Samples were prepared in cold (− 20 °C) lysis solvent (LS) consisting of methanol, acetonitrile, and H 2 O (50:30:20). Serum (isolated from terminal bleeds and stored at − 80 °C) samples of 10 μ l were added to 490 μ l of LS and vortexed, precipitated protein was cleared by centrifugation (15,000 r.p.m. for 10 mins at 4 °C). Organoid extracts were prepared by briefly washing wells with excess PBS then adding 250 μ l LS per well and placing on a rocking shaker at 4 °C for 10 min, LS was removed from wells (without mechanical disruption of organoids/Matrigel) and then vortexed and cleared by centrifugation. Tissue samples were snap-frozen and stored at − 80 °C. Prior to lysis, frozen samples were weighed. Tissues were then homogenized in 1 ml cold LS using a Precellys homogenizer (Bertin Technologies) or a TissueLyser II (Qiagen).
Lysates were cleared of protein by centrifugation and lysate concentrations normalized post-homogenization with LS to 10 mg ml −1 based on original tissue weight. Extracts were analysed on an LC-MS platform consisting of an Accela 600 LC system and an Exactive mass spectrometer (Thermo Scientific). Two LC methods were applied for metabolite separation before MS detection. Method 1 employed a SeQuant ZIC-pHILIC column (2.1 mm × 150 mm, 5 μ m) (Merck) with the mobile phase mixed by A = ammonium carbonate 20 mM (adjusted to pH 9.4) and B = acetonitrile. A gradient program starting at 20% of A and after 2 min linearly increasing to 80% at 17 min was used followed by washing and re-equilibration steps. The total run time of the method 1 was 25 min. Method 2 employed a ZIC-HILIC column (4.6 mm × 150 mm, 3.5 μ m) (Merck) with the mobile phase mixed by A = water with 0.1% formic acid (v/v) and B = acetonitrile with 0.1% formic acid. A gradient program starting at 20% of A and linearly increasing to 80% at 30 min was used followed by washing and re-equilibration steps. The total run time of method 2 was 46 min. The LC stream was desolvated and ionized in the HESI probe. The Exactive mass spectrometer was operated in full-scan mode over a mass range of 75-1,000 m/z at a resolution of 50,000 with polarity switching. LC-MS quantification of serine and glycine was achieved with six-point standard curves using 13 C-15 N-labelled amino acids (Sigma-Aldrich) diluted in a relevant matrix matched to the analytical sample. The raw data was analysed by LCquan (Thermo Scientific) and MZMine 2.10 for metabolite identification and quantification. Unbiased metabolomics. Raw LC-MS data was converted into mzML files using ProteoWizard and imported into MZMine 2.10 for peak extraction and sample alignment. The generated.csv file was imported into an in-house macro (Microsoft Excel 2010) for metabolite identification and removal of background signals. The detailed procedure and setting parameters are previously described 37 . SIMCA 14 (Umetrics) was used for multivariate analysis. The S-plots were produced in OPLS-DA (orthogonal partial least squares discriminant analysis) models for targeting the most influential metabolites. Diets. From weaning, mice received 'normal chow' (Rat and Mouse Breeder and Grower, 801730, Special Diet Services, SDS, UK) and water ad libitum. On normal chow, dietary amino acids are derived from whole proteins contained in the raw ingredients (wheat, wheatfeed, barley, de-hulled extracted toasted soya, maize and fish meal), with a small amount of purified lysine added as a supplement. Two sets of experimental diets were used, both based on Baker Purified Amino Acid Diet 38 from TestDiet (Richmond, IN): 'Diet 1-Control' contained all essential amino acids plus serine, glycine, glutamine, arginine, cystine, and tyrosine; 'Diet 1-SG-free' was the same as Diet 1-Control, but without serine and glycine, with the other amino acid levels increased proportionally to achieve the same total amino acid content. These 'Diet 1' formulations contain the same set of amino acids used previously 7 . 'Diet 2-Control' contained all essential amino acids plus serine, glycine, glutamine, arginine, cystine, tyrosine, alanine, proline, glutamate and asparagine; 'Diet 2-SG-free' was the same as Diet 2-Control, but without serine and glycine, with the other amino acid levels increased proportionally to achieve the same total amino acid content. 'Diet 2' formulations were used for the Eμ-Myc;Tigar experiment (Fig. 2f) ). Intestines were fixed in methacarn (4:2:1 ratio of methanol, chloroform, acetic acid) to facilitate scoring letter reSeArCH of tumour number and measurement of tumour area (width × length for each adenoma). Apart from n = 6 Apc min/+ mice, which were taken at a temporal end point for BrdU and caspase staining, all other GEMMs were killed at humane clinical end point.
Sample sizes for mouse studies were estimated from previous experience with these models where potential differences in survival are tested by Mantel-Cox (log rank) analysis. No statistical methods were used to predetermine sample size. After data was collected for the first experimental groups (for example, Eμ-Myc and Apc Min/+ on diet only, Fig. 1a, b ) subsequent groups were reduced in size to minimize animal numbers used (for example, phenformin and metformin treatment groups, Fig. 2a, b) . In all experiments mice with overt phenotype at time of enrolment into the study were excluded (that is, not enrolled): for example, enlarged lymph nodes or signs of enlarged thymus in the Eμ-Myc cohorts, anaemia in the Apc Min/+ cohorts. Animals that died as a result of illness unrelated to tumour(s) were included as censored observations. Mice were allocated into the experimental groups according to a randomized block design: as mice became available through breeding, they were split into blocks based on gender and then randomly assigned to a treatment arm. Care was taken to keep the male/female ratio similar in order to remove gender as a potential source of variability. The investigator allocating mice to the experimental groups and collecting the end point data was not blinded. Eμ-Myc lymphoma cells were isolated from tumour bearing lymph nodes of mixed background Eμ-Myc mice by FACS. These cells were initially expanded in cell culture with irradiated mouse embryonic fibroblasts (MEFs) and passaged until they could grow independently. Culture medium was DMEM/F-12 (Gibco, Thermo Fisher Scientific) supplemented with 10% FBS, 50 μ M β -mercaptoethanol, penicillin, streptomycin, gentamycin and amphotericin. Cells were implanted by bilateral subcutaneous injections (5 × 10 5 cells per flank) into CD1-Nude female mice (Charles River, UK). Mice were maintained on normal chow diet and monitored daily until visible, measurable tumours (~ 5 mm) had formed. Tumourbearing mice were placed onto control or SG-free diets, tumours were measured with callipers every 2 or 3 days. Once the first mouse in the cohort reached clinical end point (maximum permitted tumour size) all mice in the cohort were killed and tumours removed (this occurred after 6 days on diet). Tumours were fixed in formalin, paraffin-embedded and sections cut for histology.
All experiments adhered strictly to the limits of the project licence authority (maximum permitted tumour size of 15 mm or ulceration), at which point the animals were humanely killed. In none of the experiments were these limits exceeded. BrdU and caspase staining and necrosis quantification. Two hours before death, mice were injected with 250 μ l of cell proliferation labelling reagent containing BrdU (RPN201, Amersham/GE Heathcare). Antibodies used: cleaved caspase 3 ASP-175 (Cell Signaling Technology, 9661), anti-BrdU (BD Biosciences, 347580) and EnVision anti-rabbit (Dako, K4003). Tissue sections were counterstained with haematoxylin Z (CellPath). Stained slides were scanned using a Leica SCN400F scanner and analysed using HALO Image analysis software (Indica Labs). For Eμ-Myc tumours cell number and BrdU and caspase staining were quantified across the whole tumour with necrotic areas excluded. For Apc Min/+ mice, single cross-sections of the entire small intestine were analysed, adenomas were manually identified and cell number, caspase and BrdU staining in each adenoma was quantified and averaged for each mouse. Necrosis was quantified using haematoxylin and eosin (H&E)-stained whole tumour cross-sections, necrotic areas were manually defined using HALO software and total necrotic versus non-necrotic surface area were calculated. Glucose and lactate quantification. Serum (from terminal blood samples) from mouse cohorts were analysed for glucose and lactate levels using a YSI 2950 Biochemistry Analyser (Xylem) according to the manufacturer's instruction. Macropinocytosis assay. Analysis of macropinocytosis was based on a previously descried protocol 31 . Initially, iKras cells were grown with (Kras-ON) or without (Kras-OFF) doxycycline for 48 h. Cells were then seeded onto glass coverslips in medium with or without doxycycline and with or without SG. After 24 h the medium was replaced with matched medium lacking FBS and left for a further 16 h. Finally, medium was replaced with matched medium containing 10% FBS and tetramethylrhodamine-labelled dextran (TMR-dextran, Thermo Fisher Scientific) particles (0.5 mg ml −1 ). After 30 min with dextran, cells were washed with PBS and fixed in 4% formaldehyde. Cells were counterstained with DAPI and green Whole Cell Stain (Thermo Scientific) and mounted in Vectasheild Hardset (Vector Laboratories). Images were captured on an Olympus FV1000 inverted laser scanning confocal microscope and dextran uptake was quantified using ImageJ/Fiji image analysis software. Western blot. Western blots on cells were performed as described previously 6, 7, 43 . In brief, whole-cell protein lysates were prepared in RIPA buffer supplemented with complete protease inhibitors (Roche), sodium orthovanadate, and sodium fluoride (both Sigma-Aldrich). Tissue samples were lysed in RIPA buffer supplemented with protease and phosphatase inhibitor cocktail (Pierce/Thermo Scientific) using a TissueLyser II (Qiagen). Lysates were cleared by centrifugation and separated using precast 4-12% 'NuPAGE' or 'Bolt' gels (Invitrogen, Life Technologies) and transferred to nitrocellulose membranes. Proteins were detected and quantified using a Li-Cor Odyssey Infrared scanner and software (Li-Cor Biosciences). Secondary antibodies for the relevant species were IRDye680 and IRDye800 conjugated (Li-Cor Biosciences). Primary antibodies used were: PHGDH (Sigma-Aldrich Life Science, HPA021241), PSAT1 (Novus Biologicals, NBP1-32920), PSPH (Santa Cruz, sc-98683), Actin I-19-R (Santa-Cruz, sc-1616-R), pERK (phospho-p44/p42 MAPK (Erk1/2) (Thr202/Tyr204)) (Cell Signalling Technology 9101), AMPKa1 (R&D Systems, AF3197) and phospho-AMPK T172 (Cell Signalling Technology 2535). qRT-PCR. RNA was extracted from iKras cells and organoids using RNeasy kit with DNase (both Qiagen) to remove DNA. qRT-PCR was performed as described previously 7 Statistics. Statistical comparisons for survival data were calculated with Graphpad Prism (v6) software using Mantel-Cox (Log Rank) test. t-tests were either performed using Microsoft excel (v14.6.1) or Graphpad Prism (v7). Type 1/paired (for example, samples taken from the same animal) and type 2/unpaired (for example, samples taken from different animals) t-tests were used. Where no prediction was made about the direction of potential difference a two-tailed t-test was used (for example, across all amino acid levels in serum samples, Fig. 1c and Extended Data Fig. 2a) . Where pre-existing data supported a prediction in the direction of difference between samples a one-tailed t-test was used (for example, de novo serine synthesis, Fig. 4c ). Where data presented is the mean of individual data points, error bars are s.d., where data are a mean of means, error bars are s.e.m. In each instance the relevant type of t-test or error bar is specified in the figure legend. Where t-tests were performed with multiple comparisons, P values were corrected using the Holm-Sidak method using GraphPad Prism (v7) software. Data availability. Data are available in Supplementary Information and on request from the authors. were H&E stained, the scale bar for each image is 4 mm, demonstrative necrotic regions marked with arrows. Additional tumour tissue sections (marked with asterisks) are included for comparison from tumours, which developed after diet change (these three tumours were measurable 2 days post diet change and were present for 4 days on diet before end point). e, Necrosis was quantified by image analysis of necrotic and non-necrotic surface area of H&E stains for the sections shown in d. Error bars are s.d. P value was calculated by t-test (unpaired, one-tailed; Ctr, n = 5; − SG, n = 6). f, Apc Min/+ mice were placed on control diet (Ctr, n = 3) or SG-free diet (− SG, n = 3) at 80 days of age. At a single temporal end point (14 days on diet) mice were killed the small intestine was removed for histological analysis. Tissue sections were immunostained for cleaved caspase- were available (Ctr diet, n = 7; − SG diet, n = 6), serum versus tumour metformin concentrations are plotted. Metformin concentrations were determined in all samples using a six-point calibration curve using the relevant biological matrix (tissue/serum). d, Serum from Apc Min/+ mice treated with metformin was analysed for glucose and lactate levels using a YSI 2950 Biochemistry Analyser. e, Intestinal tumour organoids derived from a Vil1-creER;Apc fl/fl mouse were grown with or without serine and glycine and with or without daunorubicin at the stated concentrations for two days. Relative change (versus no drug control) in organoid diameter is plotted. Data are average of three independent experiments, error bars are s.e.m. f, Vil1-creER;Apc fl/fl organoids were grown with or without serine and glycine, and with or without daunorubicin for two days, then fixed and stained for malondialdehyde (MDA), data are average of three independent experiments, bars are s.e.m. P values calculated by t-test (unpaired, two-tailed, with correction for multiple comparisons).
